Long-term response with sunitinib for metastatic renal cell carcinoma

Abstract A 65-year-old man with metastatic renal cell carcinoma developed progressive disease after treatment with interferon-α. He began treatment with sunitinib, a multitargeted tyrosine kinase inhibitor, on clinical trial. The patient achieved a partial response after two cycles of therapy, with a durable response continuing after 2 years of treatment. This case report illustrates the long-term response to sunitinib for patients with metastatic renal cell carcinoma.